Some patients with early gastroesophageal cancer may appear to “heal” because of antisecretory medication.
However, the risk of a missed diagnosis is unknown.
Dr Annmarie Lassen and colleagues from Denmark estimated the incidence of gastroesophageal cancer.
The researchers assessed gastroesophageal cancer with or without pre-endoscopic treatment with antisecretory medication.
The research team extracted data on use of endoscopies, gastroesophageal cancer diagnoses, death, migration, and use of antisecretory medication.
The team evaluated the data from 5 population-based registries from 1974 to 2002.
| Gastroesophageal cancer during follow-up was 46 per 100,000 person-years with antisecretory medication|
All citizens in Funen County with a population of 470,000 who were investigated by endoscopy for the first time between 1993 and 2002 were included.
The patients were followed up until death, emigration, or the end of the study period.
Among 27,829 patients with a first endoscopy, 48% male were male with a mean age of 56 years and 115,804 person-years of follow-up.
The team found that 461 had gastroesophageal cancer diagnosed at the first endoscopy.
The research team observed that 52 were diagnosed during a median follow-up of 3 years after the first endoscopy.
The incidence during follow-up was similar to the background population, increased with age, and was higher in male patients.
Gastroesophageal cancer during follow-up was 46 per 100,000 person-years in users of antisecretory medication the last 180 days before the first endoscopy.
The team compared this with 44 per 100,000 person-years in nonusers.
Dr Lassen's team concludes, “Very few cancers are missed at endoscopy.”
“The risk seems similar in users and nonusers of antisecretory medication before endoscopy.”